TSC2 and lymphangioleiomyomatosis: As vascular ECs from LAM lungs do not harbor TSC1 or TSC2 mutations and do not have any previously known roles in LAM pathogenesis, it is unclear how mesenchymal LAM cells with constitutive mTORC1 hyperactivation alter vascular EC function.